Himalaya Nutravedics India Limited
Himalaya Nutravedics India Limited is an SME IPO focused on manufacturing, marketing and distributing Ayurvedic and nutraceutical formulations in India. The company also provides third-party contract manufacturing services for other Ayurvedic and nutraceutical firms.
Overview
About the Company
Himalaya Nutravedics India Limited was incorporated in June 2022 and operates in the Ayurvedic and nutraceutical sector. The company manufactures and markets a diversified portfolio including classical Ayurvedic formulations, proprietary Ayurvedic products, and nutraceutical supplements across multiple dosage forms such as soft gelatin capsules, hard gelatin capsules, tablets, liquid orals, and medicated oils. Its products address therapeutic and wellness areas including gut health, cardiac and metabolic wellness, diabetes management, pain management, immunity, women's wellness and general wellness. The business runs on a hybrid model combining its own branded products with third-party contract manufacturing services. The company operates an integrated WHO-GMP compliant manufacturing facility in Hyderabad, Telangana, holding AYUSH and FSSAI registrations along with ISO 9001:2015, ISO 22000:2018, HACCP, HALAL and KOSHER certifications. As of July 2026, it employed 86 full-time staff across marketing, production, finance, quality, compliance and administrative functions.
Company Details
📋 Objects of Issue (Use of Proceeds)
- › Funding working capital requirements: ₹13.75 crore
- › Business development and digital marketing activities: ₹7.50 crore
- › General corporate purposes: ₹5.25 crore
✅ Strengths
- ✓ Integrated manufacturing infrastructure supporting multiple dosage form production
- ✓ Diverse product range spanning Ayurvedic and nutraceutical therapeutic categories
- ✓ Established B2B distribution network covering 17 Indian states
- ✓ Strong historical revenue and profitability growth trajectory
- ✓ Comprehensive quality control systems with multiple international certifications
- ✓ Growing doctor acceptance driven by product efficacy
- ✓ Strategic expansion into direct-to-consumer digital and e-commerce channels
⚠️ Risks
- ! Heavy dependence on Ayurvedic products generating over 90% of total revenue
- ! Customer concentration risk with top 10 clients contributing more than 80% of revenue
- ! Single facility operational risk from leased manufacturing unit in Hyderabad
- ! Pending trademark opposition proceedings affecting brand protection
- ! Historical negative operating cash flows attributable to working capital requirements